StockData
Viridian Therapeutics, Inc.DE logo

Viridian Therapeutics, Inc.DE (VRDN) bonds

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30257% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Viridian Therapeutics, Inc.DE reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2019

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Viridian Therapeutics, Inc.DE's 10-Q for the period ended Jun 30, 2026

IssueCouponMaturesAmount issuedCarrying value
Convertible Senior Notes Due 2032
Convertible at $25 a share
1.75%2032$250.00M$250.00M
Hercules Loan and Security Agreement8.95%–$300.00M$50.00M
Sale of Future Revenue––$300.00M–

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

See a number that looks wrong?